Juq-139 -

In the vast expanse of the internet, certain keywords or phrases manage to capture the attention of users, sparking curiosity and encouraging exploration. One such term that has been making waves in various online communities and forums is "JUQ-139." This article aims to provide a detailed examination of what JUQ-139 refers to, its origins, and the contexts in which it is discussed.

JUQ‑139 is a newly designed heterocyclic small‑molecule that combines a 1,3‑benzothiazole core with a fused pyrazolo[1,5‑a]pyridine moiety, functionalized with a sulfonamide‑linked aryl‑alkyl side chain. The compound was conceived through a structure‑based drug‑design (SBDD) campaign targeting the ATP‑binding pocket of the oncogenic kinase (phosphoinositide 3‑kinase alpha). Here we report a convergent synthetic route to JUJ‑139, its physicochemical profiling, in‑vitro kinase inhibition, cytotoxicity against a panel of cancer cell lines, and preliminary in‑vivo efficacy in a xenograft mouse model. JUQ‑139 exhibits sub‑nanomolar affinity for PI3K‑α (K i = 0.42 nM), selective inhibition over the PI3K‑β/δ/γ isoforms (>500‑fold), and potent antiproliferative activity (IC 50 = 12–38 nM) in triple‑negative breast cancer (TNBC) and KRAS‑mutant colorectal cancer (CRC) cell lines. Oral administration (30 mg kg⁻¹ q.d.) in athymic nude mice bearing MDA‑MB‑231 xenografts produced a 78 % tumor growth inhibition (TGI) with no observable toxicity. These data position JUQ‑139 as a promising lead for further preclinical development toward targeted cancer therapy. JUQ-139